Found: 33
Select item for more details and to access through your institution.
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1341708
- By:
- Publication type:
- Article
Effective treatment of erythrasma-associated inflammation and pruritus with isoconazole nitrate and diflucortolone valerate combination therapy.
- Published in:
- Mycoses, 2013, v. 56, p. 38, doi. 10.1111/myc.12046
- By:
- Publication type:
- Article
Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 12, p. 1543, doi. 10.1111/ijd.16192
- By:
- Publication type:
- Article
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study).
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 739, doi. 10.1002/jvc2.204
- By:
- Publication type:
- Article
Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis).
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 8, p. 1, doi. 10.1111/dth.15608
- By:
- Publication type:
- Article
Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) study
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 1, p. 1, doi. 10.1111/dth.15166
- By:
- Publication type:
- Article
Can intermittent, time‐restricted circadian fasting modulate cutaneous severity of dermatological disorders? Insights from a multicenter, observational, prospective study.
- Published in:
- Dermatologic Therapy, 2021, v. 34, n. 3, p. 1, doi. 10.1111/dth.14912
- By:
- Publication type:
- Article
Biologics increase the risk of SARS‐CoV‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration.
- Published in:
- Dermatologic Therapy, 2020, v. 33, n. 5, p. 1, doi. 10.1111/dth.13475
- By:
- Publication type:
- Article
COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration.
- Published in:
- Dermatologic Therapy, 2020, v. 33, n. 4, p. 1, doi. 10.1111/dth.13508
- By:
- Publication type:
- Article
Dabigatran‐associated Acute Generalized Exanthematous Pustulosis (AGEP) in a psoriatic patient undergoing Ixekizumab and its pathogenetic mechanism.
- Published in:
- Dermatologic Therapy, 2019, v. 32, n. 5, p. N.PAG, doi. 10.1111/dth.13018
- By:
- Publication type:
- Article
From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management.
- Published in:
- Dermatologic Therapy, 2019, v. 32, n. 3, p. N.PAG, doi. 10.1111/dth.12886
- By:
- Publication type:
- Article
When IL‐17 inhibitors fail: Real‐life evidence to switch from secukinumab to adalimumab or ustekinumab.
- Published in:
- Dermatologic Therapy, 2019, v. 32, n. 2, p. N.PAG, doi. 10.1111/dth.12793
- By:
- Publication type:
- Article
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
- Published in:
- Acta Dermato-Venereologica, 2021, v. 101, n. 11, p. 1, doi. 10.2340/actadv.v101.283
- By:
- Publication type:
- Article
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. e1203, doi. 10.1111/jdv.19186
- By:
- Publication type:
- Article
Heterologous versus homologous primary and booster COVID‐19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: Insights from a real‐life, multicenter, case–control study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 6, p. e693, doi. 10.1111/jdv.18943
- By:
- Publication type:
- Article
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 5, p. 1017, doi. 10.1111/jdv.18913
- By:
- Publication type:
- Article
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 1, p. 93, doi. 10.1111/jdv.18594
- By:
- Publication type:
- Article
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
- Published in:
- 2019
- By:
- Publication type:
- journal article
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting ("Ramadan Fasting") on Hidradenitis Suppurativa: Insights from a Multicenter, Observational, Cross-Over, Pilot, Exploratory Study.
- Published in:
- Nutrients, 2019, v. 11, n. 8, p. 1781, doi. 10.3390/nu11081781
- By:
- Publication type:
- Article
The Impact of Intermittent Fasting (Ramadan Fasting) on Psoriatic Arthritis Disease Activity, Enthesitis, and Dactylitis: A Multicentre Study.
- Published in:
- Nutrients, 2019, v. 11, n. 3, p. 601, doi. 10.3390/nu11030601
- By:
- Publication type:
- Article
The Impact of Ramadan Fasting on the Reduction of PASI Score, in Moderate-To-Severe Psoriatic Patients: A Real-Life Multicenter Study.
- Published in:
- Nutrients, 2019, v. 11, n. 2, p. 277, doi. 10.3390/nu11020277
- By:
- Publication type:
- Article
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS).
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 2, p. 495, doi. 10.3390/jcm13020495
- By:
- Publication type:
- Article
SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.
- Published in:
- Frontiers in Immunology, 2021, v. 11, p. N.PAG, doi. 10.3389/fimmu.2021.635018
- By:
- Publication type:
- Article
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 3, p. 441, doi. 10.1007/s40257-019-00490-2
- By:
- Publication type:
- Article
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 847, doi. 10.2147/CCID.S400520
- By:
- Publication type:
- Article
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 27, doi. 10.2147/CCID.S378135
- By:
- Publication type:
- Article
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis).
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1649, doi. 10.1007/s13555-024-01182-4
- By:
- Publication type:
- Article
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 919, doi. 10.1007/s13555-024-01135-x
- By:
- Publication type:
- Article
Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 3, p. 351, doi. 10.1111/ijd.17005
- By:
- Publication type:
- Article
Palmoplantar pustulosis successfully treated with upadacitinib: Report of three cases.
- Published in:
- Australasian Journal of Dermatology, 2023, v. 64, n. 4, p. 568, doi. 10.1111/ajd.14142
- By:
- Publication type:
- Article
Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 1, p. 95, doi. 10.3390/ph15010095
- By:
- Publication type:
- Article